Bigul

Q2FY22 Quarterly Result Announced for Divi's Laboratories Ltd.

Highlights: Divi's Labs earns a PAT of Rs 606 crores for Q2 of FY22 on Consolidated Basis Divi's Laboratories has earned a consolidated total income of Rs 2007 crores for quarter ended 30th September 2021 as against a consolidated total income of Rs 1763 crores in the corresponding quarter of the previous year. Profit before Tax (PBT) for the quarter amounted to Rs 760 crores as against a PBT of Rs 693 crores for the corresponding quarter of the last year. Profit after Tax (PAT) for the quarter grew by 17% to Rs 606 crores as against a PAT of Rs 520 crores for the corresponding quarter of the last year. For the current quarter, we have a forex loss of Rs 7 crores as against a loss of Rs 16 crores during the corresponding quarter of last year. For the half-year ended 30th September 2021, the company earned a consolidated total income of Rs 3996 crores as against a consolidated total income of Rs 3506 crores during the previous half-year. PAT for the current half-year came to Rs 1164 crores as against Rs 1012 crores for the previous half-year. For the current half-year, we had a forex gain of Rs 13 crores as against a loss of Rs 11 crores during the corresponding period last year. Result PDF
08-11-2021

Earnings Call for Q2FY22 of Divi's Laboratories

Conference Call with Divi's Laboratories Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
07-11-2021
Bigul

Divis Laboratories Ltd - 532488 - Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2021

Further to our intimation dated October 28, 2021, we would like to inform that the Board of Directors of the Company at its meeting held on November 06, 2021 has, inter alia, approved the Unaudited Financial Results for the quarter and half year ended September 30, 2021. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 10.00 Hrs and concluded at 11.40 Hrs.
06-11-2021
Bigul

Divis Laboratories Ltd - 532488 - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2021

Further to our intimation dated October 28, 2021, we would like to inform that the Board of Directors of the Company at its meeting held on November 06, 2021 has, inter alia, approved the Unaudited Financial Results for the quarter and half year ended September 30, 2021. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and half year ended September 30, 2021 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 10.00 Hrs and concluded at 11.40 Hrs.
06-11-2021
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call for Q2FY22 to be held on November 06, 2021. This is for your information and records.
02-11-2021
Bigul

Divis Laboratories Ltd - 532488 - Board Meeting Intimation for Intimation Of Board Meeting

DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, November 06, 2021, inter-alia, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2021. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from October 01, 2021 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
28-10-2021
Bigul

Divis Laboratories Ltd - 532488 - Statement Of Investor Complaints For The Quarter Ended September 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 014140 Name of the Signatory :- M Satish ChoudhuryDesignation :- Company Secretary and Compliance Officer
14-10-2021
Bigul

Divis Laboratories Ltd - 532488 - Shareholding for the Period Ended September 30, 2021

Divis Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here
11-10-2021
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we herewith submit a certificate for the quarter ended September 30, 2021 received from M/s. KFin Technologies Private Limited, Registrar & Share Transfer Agent of the Company. This is for your information and records.
07-10-2021

Divis Labs surges 10%, hits record high in Monday's session; here's why

Merck & Co's Covid-19 antiviral pill, Molnupiravir, reduced the risk of hospitalisation or death by 50 per cent
04-10-2021
Next Page
Close

Let's Open Free Demat Account